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Abstract 
 
The specific pharmacological response evoked by a nicotinic acetylcholine receptor (nAChR) 
agonist is governed by the anatomical distribution and expression of each receptor subtype, and 
by the stoichiometry of subunits comprising each subtype.  Contributing to this complexity is the 
ability of agonists that bind to the orthosteric site of the receptor to alter the affinity state of the 
receptor and induce desensitization; and the observation that, at low doses, some nAChR 
antagonists evoke agonist-like nicotinic responses.  Brain concentrations of nicotine rarely 
increase to the low-mid μM concentrations that have been reported to evoke direct agonist like 
responses such as calcium influx or neurotransmitter release.  Low μg/kg doses of nicotine 
administered to humans or to non-human primates to improve cognition and working memory 
likely result only in low nM brain concentrations - more in line with the ability of nicotine to 
induce receptor desensitization.  Here we review data illustrating that nicotine, its major 
metabolite cotinine, and two novel analogs of choline, JWB1-84-1 and JAY2-22-33, each 
improve working memory in macaques.  The effectiveness of these four compounds in the task 
was linearly related to their effectiveness in producing desensitization of the pressor response to 
ganglionic stimulation evoked by a nAChR agonist in rats.  Only nicotine evoked an agonist-like 
action (increased resting blood pressure).  Therefore it is possible to develop new chemical 
entities that have the ability to desensitize nAChRs without an antecedent agonist action.  Since 
these “silent desensitizers” are likely acting allosterically, an additional degree of subtype 
specificity could be attained. 
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Discussion 
Nicotine Agonist or Antagonist? 
 The exploration of the actions of the tobacco alkaloid nicotine and the initial concept of 
nicotinic receptors has continued for well over 100 years.  Despite the wealth of published 
literature that is now available, the pharmacology of nicotine remains to be fully elucidated, and 
depending on the system studied the drug can evoke responses that are complex, unpredictable, 
and difficult to interpret.   Although traditionally described as a receptor agonist, the net effect of 
nicotine (i.e., agonist or functional antagonist) could depend on several factors such as the drug 
dose or concentration, the length of the time of exposure, and the affinity state of the receptor 
(reviewed, Rowell and Duggan, 1998).  The concept that the CNS effects of nicotine are due to its 
“agonist” effects at nicotinic acetylcholine receptors (nAChRs) and the subsequent increases in 
the release of neurotransmitters (as has been suggested many times) is probably overly simplistic, 
since in a number of settings, nicotine and nAChR antagonists can have very similar physiologic 
effects.   For example, the nAChR antagonists d-tubocurarine and α-bungarotoxin have been 
observed to produce neuronal excitatory responses (i.e., increased population spikes) in rodent 
hippocampal slices that were quantitatively similar to those produced by nicotine (Ropert and 
Krnjevic, 1982).  Also, both nicotine and the α7 nAChR antagonist methyllycaconitine enhanced 
long-term potentiation after their application to GABA-containing neurons in the CA1 region of 
the hippocampus (Fujii et al., 2000).  Intrahypothalamic injection of d-tubocurarine was reported 
to evoke excitatory behavioral responses (i.e., fear and escape reactions) in rats (Decsi and 
Karmos-Varszegi, 1969; Buccafusco and Brezenoff, 1980) in a fashion similar to carbachol.  
Moreover, both nicotine and mecamylamine increased serotonin release in rat dorsal hippocampal 
slices (Kenny et al., 2000); and in guinea pig striatum mecamylamine and the high-affinity 
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antagonist, dihydro-β-erythroidin, exerted effects similar to nicotine on dopamine release under 
conditions of phasic and tonic activity (Rice and Cragg, 2004).  In studies of receptor regulation, 
the chronic exposure to either nicotine or to nAChR antagonists, in vivo, has revealed similarities 
of action.  For example, chronic administration of nicotine or mecamylamine to rats increased the 
expression of [3H]-nicotine binding sites in frontal cortex (Abdulla et al., 1996) and chronic 
exposure to nicotine or mecamylamine increased the expression of cell surface NGF receptors in 
PC-12 cells (Terry and Clarke, 1994).  
 At relatively high doses mecamylamine is well documented to impair cognition across 
multiple domains.  In the lower dose range, mecamylamine has been reported to improve 
memory-related task performance similar to nicotine. For example, μg/kg doses of nicotine and 
mecamylamine each have been observed to enhance delayed matching to sample (DMTS) 
accuracy in monkeys (Buccafusco and Jackson 1991; Terry et al., 1999) and to improve the 
performance by rats of a delayed stimulus discrimination task (Terry et al., 1999).  Also in rats, 
mecamylamine dose-dependently improved working memory in a T-maze alternation task when 
30 second intervals were imposed between stimulus and response (Moran, 1993).  Supporting 
data also are derived from studies in which chronic administration of either nicotine or 
mecamylamine was reported to improve performance in a in a radial arm maze task, and in a T-
maze alternation task (see, Levin et al., 1997).   
 
 
The Case for Nicotinic Receptor Desensitization 
 The complex pharmacology of nicotine and the perplexing pharmacological similarities 
between nicotine and low doses/concentrations of the nAChR antagonists described above could 
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be due to the ability of nicotine to both activate and desensitize its receptors over a relatively 
short time course.  nAChRs can exist in various conformational states that are rapidly inter-
convertible.  Agonist binding stabilizes the desensitized state which is characterized by the high 
affinity binding of agonists.  Despite the conversion to a high affinity state, desensitization 
results in decreased responsiveness of the receptor for a subsequent stimulus.  Therefore, over 
time, there is a compensatory increase in the expression of receptor protein (up-regulation).  As 
discussed below the kinetic properties of the various subtypes of nicotinic receptors help explain 
the pharmacological responses produced by nAChR agonists and antagonists.  More relevant to 
this discussion are new compounds that alter nAChR function by binding to allosteric sites on 
the ion channel.  Some of these compounds impart interesting kinetic properties to the receptor 
protein, particularly the newly classified “silent desensitizers” that induce nAChR desensitization 
without an antecedent agonist-like response. 
 Like nicotine, the ability of cotinine, nicotine’s primary metabolite, to induce the release 
of dopamine in vitro occurs at much higher concentrations than those present in the brains of 
smokers (O’Leary et al., 2008).  Cotinine has relevance to nicotine’s actions because the 
metabolite has been reported to induce a variety of behavioral responses in animals including 
positive effects on information processing and cognitive function (Terry et al.  2005).  Because 
brain nicotine and cotinine concentrations after smoking are not sufficient to induce 
neurotransmitter release, both compounds could mediate their behavioral actions through nAChR 
desensitization.  nAChR desensitization, rather than receptor activation, is rapidly gaining 
attention as a major contributor to the behavioral actions of nicotine (Picciotto et al., 2008).  The 
large disconnect between high concentrations of nicotinic drugs used to activate nicotinic 
responses in vitro and the lower doses used to induce various behavioral responses in vivo 
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suggests that the latter are related more to the desensitized state as occurs in binding studies.  
However, even during periods of receptor desensitization nicotinic receptor-mediated activity is 
far from completely eliminated (Grady et al., 1997).  This situation could help explain the need 
for continuous exposure to nicotine by cells in culture in order for the drug to induce a 
cytoprotective action (Jonnala et al., 2002).  Clearly in such situations nAChRs exist primarily in 
the desensitized-high affinity state.  This situation helps regulate calcium influx through nAChR 
channels thus maintaining intracellular calcium levels that are pro-survival.  In tissue culture the 
question arises as to how incubation of cells with low concentrations of nAChR antagonists like 
mecamylamine results in cytoprotection.  One possibility is that incomplete antagonism could 
mimic agonist-induced desensitization which is also a form of incomplete antagonism.   Low 
concentrations of mecamylamine could limit the endogenous toxicity mediated through 
α7nAChRs (see, Lukas et al., 2001).  Thus it is possible to envision a mechanism characterized 
by partial inhibition of nAChR function that could explain the ability of agonists and antagonists 
of the receptor to evoke largely similar pharmacological responses. 
 In cultured cells, particularly those that are differentiated, both acetylcholine and choline 
can serve as agonists for nAChRs.  Choline is a low potency, but full agonist of α7nAChRs.  
Standard culture media often contain fetal bovine or calf serum, and along with contributions 
from the turnover and degradation of cell membranes contribute free choline to the cell 
environment.  Free choline in the medium of PC-12 cells grown and maintained in Dulbecco’s 
modified Eagle’s Medium/Nutrient Mixture F-12 containing 10% fetal bovine serum is about 70 
μM (Yen et al., 2002).  During long incubation periods, free choline could also be derived from 
cell membrane injury and degradation and result in activation of α7nAChRs.  Likewise, in 
primary cell cultures, during medium changes, glutamate-mediated cytotoxicity occurs 
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(Buccafusco et al., 2007a).  Both the prolonged activation of α7nAChRs, and medium change 
toxicity, have the potential for increasing intracellular calcium to levels associated with 
cytotoxicity.  Low concentrations of mecamylamine or desensitizing concentrations of nicotine 
could limit high intracellular calcium levels induced by growth factor withdrawal or by chemical 
insults such as β-amyloid or glutamate.  Further studies will be needed to confirm this 
possibility. 
 It is perhaps easier to conceive that desensitization of α7 nAChRs in vivo could induce an 
agonist-like behavioral response (e.g., improvement in working memory) through the process of 
disinhibition.  The α7 subtype is well expressed in the hippocampus, which receives 
considerable innervation from cholinergic afferents arising from the medial septum.  Presynaptic 
and postsynaptic nAChRs have been identified in layer CA1 where they are expressed by local 
circuit neurons.  Activation of these cells by nAChRs can result both in inhibition and 
disinhibition of pyramidal cells (Frazier et al., 2002).  Specifically nAChR activation has been 
reported to activate GABAergic activity in hippocampal CA1 stratum radiatum interneurons 
(Mok and Kew, 2006).  Whereas brief exposure to a very high concentration of agonist can 
produce excitatory currents in hippocampal interneurons, prolonged application leads to 
desensitization.  Moreover, desensitization of nAChRs expressed on hippocampal hilar neurons 
is produced by 250 fold lower concentrations of choline than is required for receptor activation 
(Frazier et al., 2002).  Therefore under conditions in which relatively low doses of nicotine or 
other agonists are administered, e.g., to produce an improvement in working memory, 
populations of hippocampal interneurons expressing α7 nAChRs could exist in the desensitized 
state.  A similar situation could exist following the administration of low doses of nAChR 
antagonists, although the amnestic actions produced in the higher dose range of antagonists 
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might be more difficult to explain with this simplistic model.  The ability of high doses of 
mecamylamine to enhance GABA release (a potential mechanism for its amnestic actions) has 
not been reported; however, the antagonist has been reported to induce the release of serotonin 
from hippocampal synaptosomes in vitro (Kenny et al., 2000).  Alternatively nicotinic agonists 
also induce the release of glutamate, facilitating long-term potentiation (Welsby et al. 2006), and 
the higher dose range of antagonists like mecamylamine could reduce glutamatergic transmission 
(O’Dell and Christensen, 1988).  One example involves the finding that α7 nAChR agonists 
induce a pattern of opposing responses mediated by GABAergic stratum radiatum interneurons 
in the CA1 region of the hippocampus (Wanaverbecq et al., 2007).  Agonists were shown to 
induce GABA release from target cells, but simultaneously they depressed inhibitory currents 
mediated postsynaptically by GABAA receptors.  It remains to be determined whether nAChR 
antagonists differentially inhibit these two cellular events; however, very low concentrations 
(maximally 10 nM) of methyllycaconitine blocked nAChR agonist-induced inhibition of 
GABAA-mediated currents (Wanaverbecq et al., 2007).  This degree of sensitivity to α7 nAChR 
blockade could explain the agonist-like action of low doses of mecamylamine. 
 In summary, the discussion thus far makes a case for focusing new drug development on 
compounds that desensitize nAChRs.  In fact, almost all of the new agonists developed in the 
past two decades have the potential to desensitize nAChRs; however, most of these accomplish 
this action by first activating the receptor at the orthosteric site.  The problem with this approach 
is that it has not generated very highly subtype selective ligands, and many compounds share 
side effect profiles with nicotine.  Targeting allosteric sites on nAChRs could be one approach to 
potentially improve subtype selectivity.  But if the idea is to induce desensitization without 
activation, a new type of compound is warranted. 
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The Relevance of Allosteric Binding Targets (Silent Desensitizers) 
 Positive allosteric modulators, defined as compounds that facilitate endogenous 
neurotransmission without directly stimulating the target receptors, have been known for ligand-
gated ion channel receptors, including nAChRs, for several years (see, Albuquerque et al., 2001).  
Very few such compounds have been characterized in vivo.  In addition to its property as an 
inhibitor of acetylcholinesterase, the Alzheimer’s drug galantamine has been suggested to act as 
a positive allosteric modulator of nAChRs (see, Coyle et al., 2007).  However, galantamine’s 
allosteric effects in vivo will always be overshadowed by its anti-cholinesterase activity.  A more 
relevant proof of concept is derived from studies with the compound PNU-120596 (1-(5-chloro-
2,4-dimethoxy-phenyl)-3-(5-methyl-isoxazol-3-yl)-urea) which has been demonstrated to act as a 
positive allosteric modulator of nAChRs both in vitro and in vivo (Hurst et al., 2005).  PNU-
120596 inhibited the ability of amphetamine to suppress auditory gating as measured by 
auditory-evoked potential in anesthetized rats.  This property of the compound suggests its 
potential for use in schizophrenia, a disorder characterized by auditory gating deficits.  The in 
vitro, effects of PNU-120596 were shown to be mediated by α7 nAChRs.  However, positive 
allosteric modulators like PNU-120596 enable nicotinic cholinergic neurotransmission in large 
part by preventing desensitization, and on their own they cannot desensitize nAChRs. 
 If desensitization of nAChRs is to be considered a viable drug target, compounds will 
need to be developed that simply desensitize the receptor without activation – so-called “silent 
desensitizers”.   Possibly the first compound so characterized was sazetidine-A [6-(5-(((S)-
azetidin-2-yl)methoxy)pyridine-3-yl)hex-5-yn-1-ol] (Xiao et al., 2006).  Sazetidine-A exhibited 
high affinity and selectivity in equilibrium binding assays for the α4β2 subtype of nAChRs.  
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Despite its affinity for the orthosteric site of the receptor, the compound evoked no agonist like 
effect; but pretreatment for as little as 10 minutes with the drug inhibited the subsequent 
response (86Rb+ release) evoked by nicotine.  In this regard the compound was 50 fold more 
potent than the competitive antagonist dihydro-β-erythroidin.  The concept is that a silent 
desensitizer traps the receptor in a high-affinity, desensitized state.  Sazetidine-A also exhibits 
certain nicotinic-like pharmacological responses.  For example, the compound can substitute in a 
nicotine/saline discrimination task, and it exhibits epibatidine-like antinociceptive activity (see, 
Zwart et al., 2008).  Based on the premise put forth in this review, we would surmise that these 
agonist-like responses were a direct result of desensitization.  However, a more recent study with 
the compound indicates that sazetidine-A induces the release of dopamine from striatal slices, an 
effect mediated through α4β2 and α6-containing subtypes of nAChRs (Zwart et al., 2008).  Of 
particular interest was the finding that the precise stoichiometry of the α4β2 receptor was 
important for determining the potency of sazetidine-A.  Thus it remains to be determined which, 
if any, of the compound’s actions could be attributed to silent desensitization. 
 
 
Analogs of Choline 
 We synthesized a series of about 50 analogs of choline with the expectation that these 
compounds would serve as selective agonists for the α7 subtype of nAChRs (Buccafusco 2004).  
Most of the compounds were created as tertiary amine analogs so that they would have drugable 
characteristics without the need to serve as substrates for the choline transporters.  Our initial 
examination of these compounds demonstrated varying potencies and efficacies in an assay for 
cytoprotection (Buccafusco et al., 2005).  The compounds did not interact with choline 
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transporters, and with a few notable exceptions they were not inhibitors of acetylcholinesterase.  
Two lead compounds, JWB1-84-1 [2-(4-(pyridin-3-ylmethyl)piperazin-1-yl)ethanol] and JAY2-
22-33 [2-(methyl(pyridine-3-ylmethyl)amino)ethanol] were studied for other pharmacological 
properties.  JWB1-84-1 improved accuracy in a spatial working memory task by transgenic mice 
bearing the APPSWE/PS1 mutations related to Alzheimer’s disease.  The compound also improved 
delayed matching-to-sample (DMTS) task accuracy by aged monkeys and significantly reversed 
distractor-impaired accuracies in an attention deficit model in young macaques (Sood et al., 
2007).  JAY2-22-33 exhibited similar properties in this model, though not perhaps as effectively 
as JWB1-84-1 (unpublished).  Therefore, it was quite surprising to determine that neither 
compound, nor any of the other analogs that were tested exhibited any ability to displace α7-
ligands in competition binding assays.  In fact, the compounds were ineffective in displacing 
other labeled nAChR ligands such as [3H]-epibatidine from binding sites on rat brain membranes.  
JWB1-84-1 and JAY2-22-33 (10 μM) also were submitted for activity in a limited 
neurotransmitter screen (NIMH Psychoactive Drug Screening Program, University of North 
Carolina at Chapel Hill).  There were no significant interactions in the screen of 40 potential drug 
targets except perhaps between JAY2-22-33 and H3 histamine receptors, but this interaction has 
not been confirmed.   So we were left with a series of interesting compounds with significant 
therapeutic potential, but with no mechanism of action to consider. 
 Fortunately we were able to derive some insight from our parallel studies of cotinine, which 
seemed to present the same conundrums as did the choline analogs.  As mentioned above, 
cotinine exhibits several nicotine-like properties (Buccafusco and Terry, 2003): (1) In the rat, the 
motor response to acoustic startle can be inhibited by the presentation of a low-level acoustic 
prepulse presented just in advance of the high-level acoustic pulse, thereby providing a measure 
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of sensory gating.  Treatment with cotinine significantly reversed the effects of apomorphine on 
acoustic startle.  (2) Cotinine was effective in preventing the cytotoxicity associated with growth 
factor withdrawal in differentiated PC12 cells.  In this regard cotinine was slightly more potent 
than nicotine.  (3) Cotinine produced a dose-dependent increase in accuracy in an automated 
DMTS task by Rhesus monkeys.  Cotinine has been characterized as a weak nicotinic agonist 
capable of evoking partial nAChR desensitization (Briggs et al., 1999; Vainio and Tuominen, 
2001).  We recently confirmed the ability of cotinine to partially desensitize ganglionic nicotinic 
receptors in vivo with no apparent activation of the receptor.  In this paradigm, both nicotine and 
cotinine readily desensitized nAChRs to the stimulus properties of the ganglionic, nicotinic 
agonist dimethylphenylpiperazinium (DMPP).  Acute injection of DMPP induced a dose-related 
increase mean arterial blood pressure in freely moving rats.  In this regard, cotinine produced no 
significant effects on blood pressure of its own at up to 13 times the dose of nicotine (Buccafusco 
et el., 2007b).   
 Thus it was no great leap of insight to then evaluate JWB1-84-1 and JWB2-22-33 in the 
DMPP paradigm.  Adult rats were instrumented to allow the continuous recording of blood 
pressure via previously implanted aortic catheters, and for the intravenous infusion of drug 
solutions through a catheter implanted in the jugular vein (for experimental details see 
Buccafusco et al., 2007b).   Test compound or vehicle (sterile, heparinized saline) was infused 
over a 20 minute period, followed by a 5 minute rest interval during which pre-injection MAPs 
were obtained.  At the end of the interval 40 μg/kg DMPP was injected as a bolus to produce a 
short-lived (about 10 min) but dramatic (up to 40 mmHg) increase in MAP.  Figure 1A shows the 
potential agonist effect of four compounds, nicotine, cotinine, JWB1-84-1 and JWB2-22-33, i.e., 
the ability of each compound to increase MAP during the infusion period.  Only nicotine 
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exhibited agonist-like activity at the highest dose.  Figure 1B depicts the DMPP-induced increase 
in MAP measured after the 20 minute infusion of test compound determined as the area beneath 
the MAP-time curve for the first 10 min after DMPP injection.  Data are presented as % vehicle 
control; the smaller the mean value the greater the degree of desensitization of ganglionic 
nAChRs.  Though cotinine appeared to be most efficacious in this regard, JWB1-84-1 evoked a 
response that was nearly as effective, but was observable across a wider dose range.   
 All four compounds were studied in the same DMTS task in macaques (Buccafusco et al., 
1999; Terry et al., 2005; Sood et al., 2007; the data for JWB2-22-33 are unpublished).  All four 
compounds significantly improved task accuracy with predominant effects during long delay 
intervals (representing retention/retrieval components of working memory).  Figure 1C presents 
the increase in task accuracy represented as the % increase from vehicle produced by each 
compound in the primate task plotted as a function of the ability to desensitize ganglionic 
nAChRs in the rat DMPP study (i.e., the data derived from Figure 1B).  Surprisingly, there was a 
very high degree of correlation between the two.  Recognizing that we are working only with 4 
data points, the high degree of correlation between these two disparate responses to our test 
compounds at least suggests the possibility that efficacy for desensitization plays a role in the 
positive mnemonic responses produced by these compounds.  The hypothesis is modeled in 
Figure 2.  It presumes that there is a direct relationship between the three systems: acetylcholine 
activates nicotinic receptors on GABA interneurons in the hippocampus which in turn leads to 
inhibition of primary hippocampal glutamate neurons.  This situation would keep activation of 
glutamate neurons under check during normal non-learning or non-remembering situations.  
When acetylcholine is over-activated (as with cholinesterase inhibitors) or when a nAChR agonist 
is administered, the first response is further activation of the GABA interneuron.  But because α7 
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nAChRs rapidly desensitize, the acetylcholine input is lost, and the glutamate neuron is released 
from GABA inhibition (disinhibited).  This disinhibition leads to glutamate release onto other 
hippocampal neurons involved in memory and the activation of LTP (long-term potentiation) 
which is an underlying substrate for memory. 
 Clearly the situation is more complicated.  However, the model provides a basis for new drug 
discovery.  Not only do allosteric nAChR compounds exhibit subtype specificity, but they could 
potentially be specific for various combinations and stoichiometries of subunits (Zwart et al., 
2008).  This is a double edge sword.  High selectivity opens the door to specificity of action with 
reduced side effects.  However, greater knowledge of the true expression and stoichiometry of 
human nAChR subtypes will be required.  Such uncertainty enhances the need for animal testing, 
and particularly for studies of efficacy in non-human primates which have greater translational 
value in this regard than rodents.  Low side effect profiles also could be characteristic of silent 
desensitizers which fail to first activate ligand-gated ion channel receptors.  With the amyloid 
hypothesis in doubt (Holmes et al., 2008), the search for compounds that can both improve 
cognition and produce neuroprotection, possibly slowing the disease process, becomes 
paramount. 
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Legends for Figures 
 
Figure 1 
Relationship between ganglionic nicotinic acetylcholine receptor (nAChR) desensitization and 
the enhancement of working memory performance in two animal models.  Panel A: The 
potential agonist effect of four compounds, nicotine, cotinine, JWB1-84-1 and JWB2-22-33 as 
determined from their ability to increase mean arterial pressure (MAP) during a 20 minute 
infusion period in freely-moving rats.  Panel B: The ganglionic stimulant (DMPP)-induced 
increase in MAP measured after the infusion of test compound determined as the area beneath 
the MAP-time curve for the first 10 min after DMPP injection.  Data are presented as % vehicle 
control; the smaller the mean value the greater the degree of desensitization of ganglionic 
nAChRs.  Panel C: The increase in delayed matching-to-sample (DMTS) task accuracy by 
macaques produced by each of the four compounds represented as the % increase from vehicle 
as a function of the ability to desensitize ganglionic nAChRs in the rat DMPP study.  DMTS 
values were obtained from individual best doses (maximal increases in task accuracy) derived 
from dose-response series for each compound.  Best Dose - Short, Medium, and Long delay 
accuracies were averaged (there is little room for improvement during Zero delay trials) for each 
subject (N=8-13) and calculated as the percent of vehicle baseline accuracies.   These values 
were plotted against the average maximal decreases in MAP for each compound derived from 
Panel B.  The solid line is the linear regression though the mean values. 
 
Figure 2 
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Model of the study hypothesis.  Acetylcholine activates nicotinic acetylcholine receptors 
(nAChRs) on GABA interneurons in the hippocampus (A) which in turn leads to inhibition of 
primary hippocampal glutamate neurons.  This situation would keep activation of glutamate 
neurons under check during normal non-learning or non-remembering situations.  Because α7 
nAChRs rapidly desensitize, the acetylcholine input to GABA interneurons is reduced (B), and 
the normally robust GABA output (C) is dramatically reduced (D), thereby releasing the 
glutamate neuron from GABA inhibition.  This disinhibition leads to enhanced glutamate release 
onto other hippocampal neurons involved in memory and the activation of LTP (long-term 
potentiation) which is an underlying substrate for memory. 
 
 


